

CLAIMS

1. A hybridoma, wherein said hybridoma produces at least 200 mg/L of a human sequence antibody when cultured in batch culture.
2. The hybridoma of claim 1, wherein said hybridoma produces at least 300
5 mg/L of said antibody.
3. The hybridoma of claim 1, wherein said hybridoma produces at least 390 mg/L of said antibody.
4. The hybridoma of claim 1 wherein the antibody is an anti-CTLA4 antibody.
5. The hybridoma of claim 4 having the identifying characteristics of the
10 hybridoma deposited at ATCC deposit number PTA-4537.
6. The hybridoma of claim 1 that is derived from the hybridoma deposited at ATCC deposit number PTA-4537.
7. The hybridoma of claim 1, wherein the hybridoma is a murine hybridoma.
8. An antibody produced by the hybridoma of claim 1.
- 15 9. A cell culture comprising a hybridoma producing an antibody having a human amino acid sequence in animal components-free medium that produces at least 200 mg/L of said human sequence antibody.
10. A cell culture of claim 9 that produces at least 300 mg/L of said antibody.
11. A method of producing antibody comprising culturing the cell culture of claim
20 10 under conditions effective for production of said antibody and isolating said antibody from said culture.
12. An antibody produced by the method of claim 11.
13. A medium free of animal-derived components, the medium comprising 2 to
25 10 g/L Wheat Gluten Peptides, 0.85 to 0.99X eRDF Stock without HEPES Buffer, 0 to 0.5% Glycerol, 0 to 2X 2-mercaptoethanol Stock, 0.5 to 8 mM L-Glutamine, 0.5 to 5X IES Stock, 2 to 8 μ M Ascorbic Acid, 1 to 5 mM Ferric Citrate, 2 to 10 x 10⁻⁴X Lipid Stock, 0 to 0.5% Medical Antifoam C Emulsion, and 0 to 4X Pluronic F-68 (10% Stock = 100X).
14. A pharmaceutical composition for the treatment of cancer in a mammal comprising an amount of an anti-CTLA-4 antibody of claim 8 or 12 that is effective in treating
30 said cancer and a pharmaceutically acceptable carrier.
15. A method for the treatment of cancer in a mammal comprising administering to said mammal an amount of an antibody of an anti-CTLA4 antibody of claim 8 or 12 that is effective in treating said cancer.